These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. Komatsubara KM; Carvajal RD Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938 [TBL] [Abstract][Full Text] [Related]
5. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663 [TBL] [Abstract][Full Text] [Related]
6. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. Moujaess E; Haddad FG; Eid R; Kourie HR Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in melanoma: Recent advances and future directions. Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635 [TBL] [Abstract][Full Text] [Related]
8. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Khair DO; Bax HJ; Mele S; Crescioli S; Pellizzari G; Khiabany A; Nakamura M; Harris RJ; French E; Hoffmann RM; Williams IP; Cheung A; Thair B; Beales CT; Touizer E; Signell AW; Tasnova NL; Spicer JF; Josephs DH; Geh JL; MacKenzie Ross A; Healy C; Papa S; Lacy KE; Karagiannis SN Front Immunol; 2019; 10():453. PubMed ID: 30941125 [TBL] [Abstract][Full Text] [Related]
9. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Pennock GK; Chow LQ Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281 [TBL] [Abstract][Full Text] [Related]
10. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update. Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R; J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011 [TBL] [Abstract][Full Text] [Related]
11. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Buchbinder EI; Desai A Am J Clin Oncol; 2016 Feb; 39(1):98-106. PubMed ID: 26558876 [TBL] [Abstract][Full Text] [Related]
14. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825 [TBL] [Abstract][Full Text] [Related]
15. Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. Friedman CF; Postow MA Curr Oncol Rep; 2016 Apr; 18(4):21. PubMed ID: 26922327 [TBL] [Abstract][Full Text] [Related]
16. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Blank CU Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272 [TBL] [Abstract][Full Text] [Related]
18. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma? Warner AB; Postow MA Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853 [TBL] [Abstract][Full Text] [Related]
19. The role of nivolumab in melanoma. Gomes F; Serra-Bellver P; Lorigan P Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic use of anti-CTLA-4 antibodies. Blank CU; Enk A Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]